CFDE Data Portal | Search NUTM2A-AS1

	Label	Description
	NUTM2A-AS1 associations Collection (Entity type)	Associations for NUTM2A-AS1_associations
	NUTM2A-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	NUTM2A-AS1 Gene (Entity type)	ENSG00000223482 - NUTM2A antisense RNA 1
	GSE120612 etoposide leukocyte 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE145195 PPP2R3B overexpression 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 0 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 7 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

NUTM2A-AS1 associations

Associations for NUTM2A-AS1_associations

NUTM2A-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

NUTM2A-AS1

ENSG00000223482 - NUTM2A antisense RNA 1

GSE120612 etoposide leukocyte 6 v 1 human up

A Gene Set from LINCS

GSE145195 PPP2R3B overexpression 0 v 1 human dn

A Gene Set from LINCS

GSE162892 ISOX 3 v 2 human dn

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 0 v 6 human dn

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 7 v 11 human up

A Gene Set from LINCS

GSE239844 crizotinib 6 v 0 human up

A Gene Set from LINCS

GSE239844 crizotinib 7 v 2 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.